Compare Hyatt Hotels Corporation (H) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hyatt Hotels Corporation vs Natera Inc. Common Stock — how do they compare? Hyatt Hotels Corporation trades at $160.32 (market cap $15.35B), while Natera Inc. Common Stock trades at $394.6 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 3.7× Hyatt Hotels Corporation's market cap, and Hyatt Hotels Corporation pays a 0.37% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hyatt Hotels Corporation for 149 Days and Natera Inc. Common Stock for 0 Days on average.
| H | NTRA | |
|---|---|---|
Market Cap | $15.35B | $57.03B |
Volume | 614,954 | 1,131,157 |
Sector | Consumer Cyclical | Health |
52-Week High | $202.09 | $425.64 |
52-Week Low | $135.42 | $179.42 |
Typical Hold Time | 149 Days | 0 Days |
Enterprise Value | $19.26B | $56.18B |
Dividend Yield | 0.37% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hyatt Hotels Corporation (H) trades at $160.32, down 0.53% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows a high P/E ratio of 201.14 but benefits from a strategic collaboration with Delta Air Lines and portfolio expansion. Cash flow trends indicate variability, with a net cash outflow of $227 million in 2025, while revenue grew to $7.10 billion.
The outlook is mixed: analyst consensus is a Moderate Buy with a $197.92 price target, implying 23% upside, but risks include high valuation, debt levels, and net income volatility. Growth drivers include brand expansion and loyalty partnerships, yet investors should monitor execution on profitability and macroeconomic impacts on travel demand.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Hyatt Hotels Corporation
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
